GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoVibronix Inc (STU:56R0) » Definitions » Cyclically Adjusted Price-to-FCF

NanoVibronix (STU:56R0) Cyclically Adjusted Price-to-FCF : (As of Jun. 09, 2024)


View and export this data going back to 2021. Start your Free Trial

What is NanoVibronix Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


NanoVibronix Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for NanoVibronix's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NanoVibronix Cyclically Adjusted Price-to-FCF Chart

NanoVibronix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NanoVibronix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NanoVibronix's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, NanoVibronix's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NanoVibronix's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NanoVibronix's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where NanoVibronix's Cyclically Adjusted Price-to-FCF falls into.



NanoVibronix Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

NanoVibronix's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, NanoVibronix's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.213/131.7762*131.7762
=-0.213

Current CPI (Mar. 2024) = 131.7762.

NanoVibronix Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -1.290 100.560 -1.690
201409 -1.580 100.428 -2.073
201412 -1.527 99.070 -2.031
201503 -2.107 99.621 -2.787
201506 -2.265 100.684 -2.964
201509 -1.031 100.392 -1.353
201512 -1.524 99.792 -2.012
201603 -1.445 100.470 -1.895
201606 -1.860 101.688 -2.410
201609 -1.039 101.861 -1.344
201612 -1.764 101.863 -2.282
201703 -1.655 102.862 -2.120
201706 -1.987 103.349 -2.534
201709 -1.769 104.136 -2.239
201712 -2.161 104.011 -2.738
201803 -2.196 105.290 -2.748
201806 -2.688 106.317 -3.332
201809 -2.130 106.507 -2.635
201812 -2.382 105.998 -2.961
201903 -2.489 107.251 -3.058
201906 -2.068 108.070 -2.522
201909 -2.864 108.329 -3.484
201912 -2.867 108.420 -3.485
202003 -2.231 108.902 -2.700
202006 -1.182 108.767 -1.432
202009 -1.263 109.815 -1.516
202012 -1.020 109.897 -1.223
202103 -0.664 111.754 -0.783
202106 -1.283 114.631 -1.475
202109 -0.414 115.734 -0.471
202112 -0.597 117.630 -0.669
202203 -1.129 121.301 -1.226
202206 -1.351 125.017 -1.424
202209 -1.417 125.227 -1.491
202212 -0.849 125.222 -0.893
202303 -0.679 127.348 -0.703
202306 -0.682 128.729 -0.698
202309 -0.371 129.860 -0.376
202312 -0.229 129.419 -0.233
202403 -0.213 131.776 -0.213

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NanoVibronix  (STU:56R0) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


NanoVibronix Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of NanoVibronix's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


NanoVibronix (STU:56R0) Business Description

Traded in Other Exchanges
Address
525 Executive Boulevard, Elmsford, New York, NY, USA, 10523
NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low frequency, low intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.

NanoVibronix (STU:56R0) Headlines

No Headlines